AZD2171 (Cediranib) is active in first line metastatic renal cell carcinoma (RCC): Interim results of a phase II trial. A trial of the PMH Phase II Consortium Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Sridhar, Srikala S
  • Mackenzie, Mary J
  • Hotte, Sebastien
  • Mukherjee, Som
  • Murray, Nevin
  • Tannock, Ian F
  • Haider, Masoom A
  • Chen, Eric X
  • Wang, Lisa
  • Srinivasan, Ranuka
  • Ivy, S Percy
  • Moore, Malcolm J

publication date

  • December 1, 2007